Hege Russnes1,2, Giske Ursin3,4,5, Anna L V Johansson6,7, Cassia B Trewin8, Irma Fredriksson9,10, Kristin V Reinertsen11. 1. Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 2. Department of Pathology, Oslo University Hospital, Oslo, Norway. 3. Cancer Registry of Norway, Oslo, Norway. 4. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. 5. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. 6. Cancer Registry of Norway, Oslo, Norway. anna.johansson@ki.se. 7. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, P.O.Box 281, SE-17177, Stockholm, Sweden. anna.johansson@ki.se. 8. Department of Registration, Cancer Registry of Norway, Oslo, Norway. 9. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 10. Department of Breast and Endocrine Surgery, Karolinska University Hospital Solna, Stockholm, Sweden. 11. Department of Oncology, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND: In breast cancer, immunohistochemistry (IHC) subtypes, together with grade and stage, are well-known independent predictors of breast cancer death. Given the immense changes in breast cancer treatment and survival over time, we used recent population-based data to test the combined influence of IHC subtypes, grade and stage on breast cancer death. METHODS: We identified 24,137 women with invasive breast cancer aged 20 to 74 between 2005 and 2015 in the database of the Cancer Registry of Norway. Kaplan-Meier curves, mortality rates and adjusted hazard ratios for breast cancer death were estimated by IHC subtypes, grade, tumour size and nodal status during 13 years of follow-up. RESULTS: Within all IHC subtypes, grade, tumour size and nodal status were independent predictors of breast cancer death. When combining all prognostic factors, the risk of death was 20- to 40-fold higher in the worst groups compared to the group with the smallest size, low grade and ER+PR+HER2- status. Among node-negative ER+HER2- tumours, larger size conferred a significantly increased breast cancer mortality. ER+PR-HER2- tumours of high grade and advanced stage showed particularly high breast cancer mortality similar to TNBC. When examining early versus late mortality, grade, size and nodal status explained most of the late (> 5 years) mortality among ER+ subtypes. CONCLUSIONS: There is a wide range of risks of dying from breast cancer, also across small breast tumours of low/intermediate grade, and among node-negative tumours. Thus, even with modern breast cancer treatment, stage, grade and molecular subtype (reflected by IHC subtypes) matter for prognosis.
BACKGROUND: In breast cancer, immunohistochemistry (IHC) subtypes, together with grade and stage, are well-known independent predictors of breast cancer death. Given the immense changes in breast cancer treatment and survival over time, we used recent population-based data to test the combined influence of IHC subtypes, grade and stage on breast cancer death. METHODS: We identified 24,137 women with invasive breast cancer aged 20 to 74 between 2005 and 2015 in the database of the Cancer Registry of Norway. Kaplan-Meier curves, mortality rates and adjusted hazard ratios for breast cancer death were estimated by IHC subtypes, grade, tumour size and nodal status during 13 years of follow-up. RESULTS: Within all IHC subtypes, grade, tumour size and nodal status were independent predictors of breast cancer death. When combining all prognostic factors, the risk of death was 20- to 40-fold higher in the worst groups compared to the group with the smallest size, low grade and ER+PR+HER2- status. Among node-negative ER+HER2- tumours, larger size conferred a significantly increased breast cancer mortality. ER+PR-HER2- tumours of high grade and advanced stage showed particularly high breast cancer mortality similar to TNBC. When examining early versus late mortality, grade, size and nodal status explained most of the late (> 5 years) mortality among ER+ subtypes. CONCLUSIONS: There is a wide range of risks of dying from breast cancer, also across small breast tumours of low/intermediate grade, and among node-negative tumours. Thus, even with modern breast cancer treatment, stage, grade and molecular subtype (reflected by IHC subtypes) matter for prognosis.
Entities:
Keywords:
Breast cancer; ER; Grade; HER2; IHC subtype; Ki67; PR; Survival/death; TNM stage; pTN status
Authors: Hanna Fredholm; Kristina Magnusson; Linda S Lindström; Nicholas P Tobin; Henrik Lindman; Jonas Bergh; Lars Holmberg; Fredrik Pontén; Jan Frisell; Irma Fredriksson Journal: Eur J Cancer Date: 2017-08-29 Impact factor: 9.162
Authors: Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart Journal: N Engl J Med Date: 2016-08-25 Impact factor: 91.245
Authors: Milena Sant; Claudia Allemani; Riccardo Capocaccia; Timo Hakulinen; Tiiu Aareleid; Jan Willem Coebergh; Michel P Coleman; Pascale Grosclaude; Carmen Martinez; Janine Bell; Judith Youngson; Franco Berrino Journal: Int J Cancer Date: 2003-09-01 Impact factor: 7.396
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Christos Sotiriou; Pratyaksha Wirapati; Sherene Loi; Adrian Harris; Steve Fox; Johanna Smeds; Hans Nordgren; Pierre Farmer; Viviane Praz; Benjamin Haibe-Kains; Christine Desmedt; Denis Larsimont; Fatima Cardoso; Hans Peterse; Dimitry Nuyten; Marc Buyse; Marc J Van de Vijver; Jonas Bergh; Martine Piccart; Mauro Delorenzi Journal: J Natl Cancer Inst Date: 2006-02-15 Impact factor: 13.506
Authors: Claudia Allemani; Milena Sant; Hannah K Weir; Lisa C Richardson; Paolo Baili; Hans Storm; Sabine Siesling; Ana Torrella-Ramos; Adri C Voogd; Tiiu Aareleid; Eva Ardanaz; Franco Berrino; Magdalena Bielska-Lasota; Susan Bolick; Claudia Cirilli; Marc Colonna; Paolo Contiero; Rosemary Cress; Emanuele Crocetti; John P Fulton; Pascale Grosclaude; Timo Hakulinen; M Isabel Izarzugaza; Per Malmström; Karin Peignaux; Maja Primic-Žakelj; Jadwiga Rachtan; Chakameh Safaei Diba; Maria-José Sánchez; Maria J Schymura; Tiefu Shen; Adele Traina; Laufey Tryggvadottir; Rosario Tumino; Michel Velten; Marina Vercelli; Holly J Wolf; Anne-Sophie Woronoff; Xiaocheng Wu; Michel P Coleman Journal: Int J Cancer Date: 2012-09-18 Impact factor: 7.396
Authors: Li Tao; Scarlett Lin Gomez; Theresa H M Keegan; Allison W Kurian; Christina A Clarke Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-12 Impact factor: 4.090
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976
Authors: Kirsti V Hjerkind; Anna L V Johansson; Cassia B Trewin; Hege G Russnes; Giske Ursin Journal: Breast Cancer Res Date: 2022-01-10 Impact factor: 8.408
Authors: Ramon Clèries; Maria Buxó; Mireia Vilardell; Alberto Ameijide; José Miguel Martínez; Rebeca Font; Rafael Marcos-Gragera; Montse Puigdemont; Gemma Viñas; Marià Carulla; Josep Alfons Espinàs; Jaume Galceran; Ángel Izquierdo; Josep Maria Borràs Journal: Int J Environ Res Public Health Date: 2022-03-18 Impact factor: 3.390